KOSDAQBiotech & Pharma215380

Woojung Bio

₩1,719▼ 2.88%2026-11-18 close
Market Cap
₩28.9B
Turnover
₩26,764,239
Volume
20K
Shares out.
16.8M
PER
—
PBR
1.2×
EPS
-₩21
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue rebounds, operating breakeven still pending

Kolmar BioTech's revenue rose to KRW 16.1 billion in the third quarter of 2026, yet its operating loss widened to KRW 1.28 billion, so whether the sales recovery converts into profit is the key question.

  1. 1

    Third-quarter 2026 revenue reached KRW 16.1 billion, up 46.2% from the prior quarter and up 64.6% from a year earlier.

  2. 2

    Operating losses persisted in the second and third quarters of 2026, and the third-quarter operating loss of KRW 1.28 billion was larger than a year earlier.

  3. 3

    Annual operating profit turned positive at KRW 1.78 billion in 2024 but returned to an operating loss of KRW 3.9 billion in 2025.

  4. 4

    The debt ratio stood at 271.3% at the end of 2025, and operating cash flow was negative in each year from 2023 to 2025.

  5. 5

    Restructuring is underway, with the absorption of a wholly owned subsidiary in July 2026 and the launch of a bio collaboration platform in October 2026.

02

Business structure

Kolmar BioTech (formerly Woojung BIO) became part of Kolmar Holdings in March 2026 and changed its name in July 2026. Its core business is bio research infrastructure and a bioclusters business built on non-clinical contract research (CRO), operated from the Kolmar Bio Cluster in Hwaseong, Gyeonggi.

The company says it is widening into cosmetic raw materials, veterinary medicines, active pharmaceutical ingredients (API) and food ingredients. Daily Pharm reported that the bio CRO business accounts for roughly 20% of sales, which implies that most revenue comes from other areas.

A wholly owned cosmetic raw-materials subsidiary was acquired on June 30, 2026 for KRW 830 million and then absorbed in a small merger with a 1-to-0 ratio and no new shares issued. That subsidiary reported 2025 revenue of KRW 1.55 billion and a net loss of KRW 16.75 million.

The merger date was set at September 22, 2026. On October 21, 2026 the company launched the Bio-One Infinity platform, covering six fields including advanced bio technology, ultra-precision diagnostics, advanced regenerative therapy, environment-clean vaccines, AI bio R&D and specialty business.

Eight core companies joined the launch, and supply agreements and joint service development have already entered execution. Against large-scale CDMO players, this company is a small bio firm concentrated in niche areas such as non-clinical CRO and cosmetic raw materials.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩9.8B-₩900M−9.0%
2025Q4₩12.4B-₩13,400,511−0.1%
2026Q1₩11B₩400M3.9%
2026Q2₩11B-₩19,091,894−0.2%
2026Q3₩16.1B-₩1.3B−8.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩46.9B-₩2.5B-₩1.9B−5.4%−6.3%219.6%
2023₩38.6B-₩4.5B-₩5.1B−11.5%−23.0%347.5%
2024₩43.2B₩1.8B₩200M4.1%0.8%222.4%
2025₩37.6B-₩3.9B-₩5.5B−10.4%−23.7%271.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 46.9 billion in 2022 to KRW 38.6 billion in 2023, a decline of 17.7%, then recovered to KRW 43.2 billion in 2024, up 11.9%, before dropping to KRW 37.6 billion in 2025, down 13.0%. 2022 was the largest revenue year in the disclosed period and 2025 the smallest.

Operating loss widened from KRW 2.52 billion in 2022 to KRW 4.46 billion in 2023. The company swung to operating profit of KRW 1.78 billion in 2024 but returned to an operating loss of KRW 3.9 billion in 2025. Operating margin was -5.4% in 2022, -11.5% in 2023, 4.1% in 2024 and -10.4% in 2025.

Net income attributable to controlling shareholders was KRW 225 million in 2024, while 2025 posted a loss of KRW 5.55 billion. Net income including non-controlling interests was a loss of KRW 5.55 billion in 2025 as well.

Operating cash flow was KRW 2.5 billion in 2022, then minus KRW 3.22 billion in 2023, minus KRW 1.13 billion in 2024 and minus KRW 630 million in 2025.

The debt ratio was 219.6% in 2022, 347.5% in 2023, 222.4% in 2024 and 271.3% in 2025, with total liabilities of KRW 63.4 billion and total equity of KRW 23.4 billion at the end of 2025.

On a quarterly basis, revenue moved from KRW 9.76 billion in the third quarter of 2025 to KRW 12.4 billion in the fourth quarter (up 27.4% from the prior quarter), KRW 11 billion in the first quarter of 2026 (down 11.3%), KRW 11 billion in the second quarter (down 0.4%), and KRW 16.1 billion in the third quarter of 2026 (up 46.2%).

The third-quarter operating loss of KRW 1.28 billion was larger than the second-quarter loss of KRW 19.09 million, after an operating profit of KRW 429 million in the first quarter of 2026.

Net income attributable to controlling shareholders was a profit of KRW 3.37 billion in the second quarter of 2026 but a loss of KRW 2.2 billion in the third quarter. The second quarter is a case where operating and net results moved in different directions, so non-operating items need to be considered alongside it. Over the last four quarters, the net loss attributable to controlling shareholders totaled KRW 347 million.

05

Industry analysis

Korean bio collaboration has seen more than 200 MOUs a year, yet only about 10% are reported to convert into actual business. Kolmar BioTech builds its platform on that gap, connecting R&D with commercialization, production and sales.

Daily Pharm reported that the CRO industry is in a downturn and framed improving the CRO business as the company's key challenge. Non-clinical CRO earnings depend on research demand from domestic bio developers, and as a Kolmar Group affiliate the company can use the group's R&D and sales infrastructure.

In cosmetics, the company says it will apply research capabilities built in cosmetic CDMO work to its bio business. The cosmetic raw-materials move looks like a relocation of group operations into the listed entity.

Large CDMO peers such as Samsung Biologics and Celltrion rely on large-scale production capacity, so their business models differ from this company's. Its competitive position is therefore better judged within narrow niches such as non-clinical CRO and cosmetic raw materials than against large producers.

06

Outlook

The company says it will run Bio-One Infinity as a business-execution structure rather than a loose consortium. Participating firms will jointly pursue R&D, commercialization and production projects, combining near-term revenue projects with longer-term technology work.

A joint sales system under a shared brand is also planned. The company has said it will pursue incorporation of the platform, without disclosing a timetable.

For the subsidiary merger, the stated aims are lower administrative costs through shared infrastructure and wider customer diversification using Kolmar Group resources. The effect will depend on whether the merged cosmetic raw-materials business keeps its sales growth while reducing its higher cost burden.

Third-quarter 2026 revenue reached KRW 16.1 billion, so whether that level holds in the following quarters is the next checkpoint. Narrowing operating losses also requires improvement in cost structure and selling and administrative expenses.

The 2026 annual report will show how full-year operating margin and operating cash flow ended. Outside 2024, operating losses persisted across the disclosed years, so whether the swing to profit is one-off or sustained can be assessed only with the next periodic reports.

07

Valuation

PER
—
PBR
1.2×
ROE
-1.4%
EPS
-₩21
BPS
₩1,464
Dividend per share
₩0

Because the net loss attributable to controlling shareholders over the last four quarters is negative, the price-to-earnings ratio cannot be calculated. The price-to-book ratio sits slightly above 1x, a modest premium to net asset value.

Total equity and equity attributable to controlling shareholders are disclosed as the same amount, so non-controlling interests play a limited role in that comparison. Shareholder returns are low, which limits any yield-based comparison.

Operating losses in most disclosed years, with 2024 the only profit year, mean earnings-based multiples have little continuity in the historical data. Profit and loss moved from loss to profit and back to loss between 2022 and 2025, so the direction of any earnings recovery has not yet been shown to be sustained.

With a debt ratio of 271.3%, the position of the share price relative to net assets should be read alongside the balance sheet.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Sales recovery in the latest quarter

Third-quarter 2026 revenue reached KRW 16.1 billion, up 46.2% from the prior quarter and up 64.6% from a year earlier. That is a clear step up from KRW 12.4 billion in the fourth quarter of 2025 and KRW 11 billion in each of the first two quarters of 2026. A larger revenue base can spread fixed costs, which is a precondition for better profitability.

Group infrastructure and merger benefits

The subsidiary was absorbed with a September 22, 2026 merger date, and the company plans to lower administrative costs by combining operations. It also intends to use Kolmar Group sales and R&D infrastructure to diversify customers. Because the merger involved no new shares, the largest shareholder is unchanged according to the disclosure.

Collaboration platform moving into execution

Bio-One Infinity launched on October 21, 2026 with six fields, including advanced bio technology, ultra-precision diagnostics and advanced regenerative therapy. Eight core companies joined, and the company says supply agreements and joint service development have already started. It runs short-term revenue projects alongside longer-term technology work.

09

Bear factors

Recurring operating losses

Operating results were a loss of KRW 2.52 billion in 2022, KRW 4.46 billion in 2023 and KRW 3.9 billion in 2025, with 2024 the only profit year. Operating losses continued in the second and third quarters of 2026, and the third-quarter loss of KRW 1.28 billion was larger than a year earlier. Revenue growth has not yet carried through to operating profitability.

CRO downturn and business mix

Daily Pharm reported that the bio CRO business accounts for roughly 20% of sales and flagged a CRO downturn as a challenge for earnings. Analysis cited in the press also suggests only about 10% of domestic bio collaborations turn into business. If CRO demand stays weak, recovery across the sales base could be constrained.

Balance sheet and cash flow

The debt ratio was 347.5% in 2023 and remained high at 271.3% in 2025. Total liabilities of KRW 63.4 billion at the end of 2025 are well above total equity of KRW 23.4 billion. Operating cash flow was negative in each year from 2023 to 2025.

A KRW 35 billion unsecured private convertible bond issued to Kolmar Holdings in March 2026 remains a financing consideration.

10

Risk factors

Earnings volatility

Net income attributable to controlling shareholders swung from a KRW 3.37 billion profit in the second quarter of 2026 to a KRW 2.2 billion loss in the third quarter. The gap between operating and net results makes it hard to read the trend from one quarter.

Over the last four quarters the cumulative net loss attributable to controlling shareholders was KRW 347 million.

Execution of restructuring

The merger's effect depends on whether the subsidiary keeps sales growth while reducing a higher cost burden. The subsidiary reported 2025 revenue of KRW 1.55 billion and a net loss of KRW 16.75 million.

The timing of the platform's incorporation has not been disclosed, which makes the restructuring's payoff hard to gauge.

Financing and balance sheet

With a debt ratio of 271.3% and negative operating cash flow, reliance on outside funding is a concern. The KRW 35 billion CB issued to Kolmar Holdings in March 2026 is a financing tool that could affect the equity structure later. Conversion terms and repayment plans need to be checked in the periodic reports.

11

What to watch next

  1. December 31, 2026

    Fiscal year 2026 ends. This is the starting point for seeing how fourth-quarter revenue and operating results feed into the full-year figures.

  2. Late March 2027

    Deadline for the 2026 annual report. The checkpoints are whether full-year operating margin turns positive and whether operating cash flow moves out of negative territory.

  3. Mid-May 2027

    Expected timing for the first-quarter 2027 quarterly report. The checkpoints are whether the third-quarter 2026 revenue level holds and whether the operating loss keeps widening.

12

Overall view

Kolmar BioTech's third-quarter 2026 revenue of KRW 16.1 billion marked a quarterly recovery, but the operating loss widened to KRW 1.28 billion. Operating profit was negative in most disclosed years from 2022 to 2025, with 2024 the exception, and the debt ratio of 271.3% remains high.

In 2026 the company restructured through the absorption of a subsidiary and the launch of Bio-One Infinity, and the no-new-shares merger left the largest shareholder unchanged. The bullish points are the sales recovery, use of group infrastructure and the platform's move into execution.

The bearish points are repeated operating losses, a weak CRO industry and balance-sheet pressure. The price-to-book ratio sits slightly above 1x, while the price-to-earnings ratio cannot be calculated.

The next checkpoints are the full-year operating margin and operating cash flow in the 2026 annual report, and whether the sales recovery holds in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. news.bizwatch.co.kr
  2. dailypharm.com
  3. hankyung.com
  4. thebionews.net
  5. kpanews.co.kr
  6. digitaltoday.co.kr
  7. kpanews.co.kr
  8. m.news.nate.com
  9. datatooza.com
  10. kolmarbiotech.com
  11. newspim.com
  12. medifonews.com
  13. kr.investing.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis